Skip to content
AdminOct 26, 2021< 1 min read

FDA, Aetion expand RWE work to focus on inpatient COVID-19 therapies

FDA and Aetion announced they will use the Aetion Evidence Platform® to gather real-world evidence on inpatient COVID-19 therapies, with the goal of demonstrating how a platform-based approach can help advance regulatory knowledge on the use of RWE and also to provide a scalable infrastructure through which therapies for coronavirus and other future infectious diseases and pandemics can be rapidly developed and evaluated.

Read More